Britain’s artificial intelligence sector has produced its first heavyweight league table of 2026, with Barclays placing Oxford-founded chip designer Fractile and Google DeepMind spinout Isomorphic Labs at the centre of its new AI 100 ranking, a list that crystallises just how quickly the UK’s AI economy is maturing.
The bank’s Eagle Labs division, the high-street lender’s start-up incubator network, unveiled the inaugural ranking this week to spotlight the country’s fastest-growing AI businesses. Its publication coincides with what is shaping up to be a record year for the sector, with UK AI companies hoovering up £8.3bn of investment in 2025 alone and cementing London’s status as Europe’s most prolific AI capital.
For Britain’s policymakers, under pressure to deliver on the Prime Minister’s pledge to “mainline AI into the veins” of the economy, the league table arrives at a politically charged moment. For investors, it offers a useful shortlist of the companies global capital is now chasing hardest.
Oxford chip pioneer joins the unicorn club
Few names on the ranking have captured boardroom attention quite like Fractile. The Oxford-founded business, set up in 2022 by former university researcher Walter Goodwin, this week banked a $220m (£165m) Series B led by Peter Thiel’s Founders Fund, with Accel and Factorial Funds joining the cheque.
The round vaults Fractile into the so-called unicorn bracket and underlines a belief among Silicon Valley’s most influential investors that the next great AI bottleneck will not be cleverer algorithms, but the eye-watering cost of running them. Mr Goodwin’s firm is racing to build inference chips that promise to slash the price of deploying AI models at commercial scale, a problem that has come to dominate boardroom conversations from Wall Street to Whitehall.
Industry watchers say the deal is one of the clearest signals yet that British deep-tech, long accused of losing its champions to American buyers, can hold its own on global capital markets. It also lands at a moment when Westminster is leaning heavily on the semiconductor sector to underpin its growth narrative, having earlier expanded backing for chip start-ups through the ChipStart programme.
Isomorphic eyes a pharma revolution
If Fractile represents the picks-and-shovels end of the AI gold rush, Isomorphic Labs sits at the other extreme. The London-based drug-discovery business, spun out of Google DeepMind in 2021 under the stewardship of Sir Demis Hassabis, recently sealed a $2.1bn (£1.57bn) funding round, one of the largest AI raises seen in Europe to date.
The company is using machine learning to accelerate the early-stage development of new medicines, an area where pharmaceutical giants have spent years grappling with stubbornly long timelines and ballooning research budgets. Big Pharma is already paying attention: AstraZeneca and Eli Lilly have inked partnerships, and a maiden in-house drug candidate is expected to enter clinical trials before the end of the year.
For an industry where the average new medicine takes more than a decade and over $2bn to bring to market, the prospect of AI compressing that timeline is no longer theoretical. It is precisely the sort of productivity dividend that researchers at HSBC say could deliver a £105bn revenue uplift to Britain’s mid-sized firms by 2030 if AI adoption keeps pace.
A boom under scrutiny
Yet for all the bullish numbers, Britain’s AI investment surge is not without its sceptics. A recent investigation by the Guardian questioned whether several headline-grabbing pledges promoted by ministers — including data-centre commitments linked to Nvidia-backed groups Nscale and CoreWeave, had been overstated.
The newspaper reported that some projects billed as brand-new infrastructure were in reality expansions of existing facilities. The Department for Science, Innovation and Technology (DSIT) rejected the bulk of the claims but conceded it was “not playing an active role in auditing these commitments”.
The episode is symptomatic of a broader credibility test now facing governments worldwide as they trumpet AI as the engine of future growth. The UK has so far announced a £500m Sovereign AI Unit and additional billions of pounds in compute and infrastructure spending, but ministers are increasingly being asked to demonstrate that the eye-catching figures translate into real jobs, factories and tax receipts.
A maturing market
Even so, the trajectory looks unmistakable. With more than £8bn raised across the sector last year, five fresh unicorns minted and at least 67 exits worth a combined £4bn, the British AI ecosystem is no longer trading on potential alone. Smaller players are also benefiting: Eagle Labs’ broader incubator network, which has supported thousands of regional start-ups through schemes such as its £12m regional grant programme, is increasingly being used as a pipeline-builder for the next cohort of AI 100 candidates.
For Barclays itself, the ranking is a useful piece of brand-building among the founders it hopes to bank for years to come. For Britain, it is something rather more consequential, an early glimpse of the companies that may, within a decade, sit alongside the country’s established corporate giants.
As one venture capitalist put it this week: “Five years ago, you’d struggle to name three UK AI businesses worth backing. Today you can’t fit them on a single page.” On the strength of Barclays’ latest list, that problem is unlikely to disappear any time soon.
Read more:
Barclays crowns Fractile and Isomorphic Labs in inaugural AI 100 as Britain’s tech race intensifies